Loading...
Freedom of Information (FOI) NHS Lothian | Our Organisation

Request and Response Register

NOTE: 100 recent requests are displayed below. Use search to find older requests.
Freedom of Information Request Reference: 11414
Date Received: 22/04/2026
Summary:
Under the Freedom of Information (Scotland) Act 2002 I would be grateful if you could provide the following information from the Chalmers Gender Identity Service. 1. Do you provide a detransition service? 2. If so please provide the protocols used to provide this service. 3. If there is no service please advise where patients are signposted to receive support in their detransition.
Date of Response: 27/05/2026
View Response: 11414.pdf
Freedom of Information Request Reference: 11423
Date Received: 28/04/2026
Summary:
The total number of sickness absence days recorded for nursing staff where the reason for absence was categorised as mental health-related. The total number of sickness absence days recorded for midwifery staff where the reason for absence was categorised as mental health-related. A breakdown of these absences by financial year and month. The number of individual absence episodes recorded for mental health-related reasons among nursing and midwifery staff in each financial year. The average length (in days) of mental health-related absence episodes in each financial year.
Date of Response: 28/05/2026
View Response: 11423.pdf
Freedom of Information Request Reference: 11418
Date Received: 23/04/2026
Summary:
Please could you provide the following information regarding the Reverse Osmosis (RO) unit currently in use in the Endoscopy Department at all of your hospitals. The make and model of the Reverse Osmosis unit. The date of installation and/or commissioning. The current age of the unit. Details of any major upgrades carried out since installation (if applicable).
Date of Response: 01/06/2026
View Response: 11418.pdf
Freedom of Information Request Reference: 11417
Date Received: 22/04/2026
Summary:
How many new patients were treated for Asthma by the Trusts Respiratory Department in the latest 4 month period (December - March 2026) with the treatments I have provided below? Please can you define a "new patient" as a patient who has received any of the treatments listed below for the first time. If a patient received any of the below treatments before the 1st August 2025, they can be classed as a new patient for the purposes of this question. · Cinqaero (Reslizumab) · Dupixent (Dupilumab) · Fasenra (Benralizumab) · Nucala (Mepolizumab) · Tezpire (Tezepelumab) · Xolair (Omalizumab) How many new patients were treated for Chronic Obstructive Pulmonary Disease (COPD) by the Trust’s Respiratory Department in the latest 4-month period (December - March 2026) with the treatments I have provided below? Please can you define a “new patient” as a patient who has received any of the treatments listed below for the first time. If a patient received any of the below treatments before the 1st August 2025, they can be classed as a new patient for the purposes of this question. · Dupixent (Dupilumab) · Nucala (Mepolizumab)
Date of Response: 01/06/2026
View Response: 11417.pdf
Freedom of Information Request Reference: 11411
Date Received: 22/04/2026
Summary:
Could you please tell me the full time equivalent staff and banding of your MSK physio department before integration of Flok and now?
Date of Response: 01/06/2026
View Response: 11411.pdf
Freedom of Information Request Reference: 11410
Date Received: 21/04/2026
Summary:
Could you please tell me how many people within your NHS area are diagnosed with Narcolepsy? This can be those with both Type 1 Narcolepsy (with Cataplexy) and those with Type 2 Narcolepsy (without Cataplexy), reported as one figure, I don’t need it broken down to Type 1 and Type 2. If possible, I would like the data reported by Council area but if that is not possible then NHS area will be sufficient.
Date of Response: 01/06/2026
View Response: 11410.pdf
Freedom of Information Request Reference: 11408
Date Received: 21/04/2026
Summary:
Section 1: System Structure & Governance Have there been any changes to your commissioning or service delivery structures in the past 24 months (including mergers, hosted services, or collaborative arrangements)? Are any services related to respiratory, transplant, or rare diseases commissioned or managed collaboratively (e.g. regional networks, hosted models, or lead‑commissioner arrangements)? Are there any planned organisational or governance changes affecting these service areas over the next 12–24 months? Section 2: Roles, Committees & Decision‑Making Which committees or governance groups hold responsibility for pathway design and medicines optimisation in: respiratory services transplant services rare disease services? Are there any named clinical leads, programme leads or specialist roles associated with these service areas? Have any new roles or groups been established in the past 18 months that influence pathway design or medicines decision‑making? Section 3: Strategic Priorities & Pressures Please list any published strategies, transformation programmes or priority documents currently relevant to: respiratory services transplant services rare disease services. Are any of these services currently subject to financial recovery, service sustainability review, or workforce mitigation activity? Are national or regional policy initiatives currently influencing planning in these areas? Section 4: Respiratory Services Are respiratory services currently undergoing pathway review or service redesign (e.g. community respiratory, diagnostics, prevention, or virtual wards)? Which respiratory disease areas are identified as priorities within current planning documents (if applicable)? Section 5: Rare Disease & Transplant Services How are rare diseases and transplant services overseen within your organisation (e.g. specialist pathways, regional networks, named leads, or national commissioning arrangements)?
Date of Response: 01/06/2026
View Response: 11408.pdf
Freedom of Information Request Reference: 11399
Date Received: 16/04/2026
Summary:
Under the Freedom of Information (Scotland) Act 2002 I would be grateful if you could provide the full list of all the organisations within your board that holds an LGBTYS charter award for organisations please.
Date of Response: 15/05/2026
View Response: 11399.pdf
Freedom of Information Request Reference: 11398
Date Received: 15/04/2026
Summary:
1. Please can you provide cost information on outsourced letter transcription for the last 3 years? 2. Please can you provide the number of letters by month not meeting a turnaround time of 7 days for the last 3 years? 3. Please can you provide the annual number of documents in backlog for the last 3 years?
Date of Response: 13/05/2026
View Response: 11398.pdf
Freedom of Information Request Reference: 11397
Date Received: 15/04/2026
Summary:
The total number of beds dedicated to end-of-life care and palliation within the health board with a breakdown of location (IE the Royal Infirmary) and ward between January 1 , 2021 - January 1 , 2026. Additionally, could I get the number of patients who had end of life or palliative care across all hospitals in the health board between January 1 , 2021 - January 1 , 2026 - if possible can I get a breakdown of those who were on a specialist ward and those who received it out with that IE on a cardiology or oncology ward etc. Could I also get the number of beds dedicated to end-of-life care and palliation that have been cut in 2026 so far also with a breakdown of location and ward.
Date of Response: 15/05/2026
View Response: 11397.pdf
Freedom of Information Request Reference: 11395
Date Received: 15/04/2026
Summary:
This FOI request is in relation to the eligibility criteria for 2026/2027 applications for staff car parking permits at the Edinburgh Royal Infirmary site. Please can you supply a copy of the site Traffic Management Group policy that was valid for applications received from 1st January 2026 that states third party (ie not NHS Lothian) employees permanently based at the RIE are ineligible to apply for a parking permit. I cannot find this on the Lothian Intranet site. I would also like to be sent evidence that this was discussed and agreed in partnership with Unite, Unison and the RCN unions.
Date of Response: 19/05/2026
View Response: 11395.pdf
Freedom of Information Request Reference: 11393
Date Received: 15/04/2026
Summary:
For each NHS Health Board in Scotland that provides healthcare services to one or more prisons, please provide details of the total workforce expenditure associated with the provision of prison healthcare. Where a Health Board is responsible for more than one prison, I would like the information provided as: 1. A total Health Board figure, and 2. A breakdown by individual prison within that Health Board area. 3. Based on 1. and 2. - the cost per prisoner for delivery of healthcare (design capacity not actual prison population) The information should relate solely to workforce costs for the provision of healthcare services within prisons (i.e. clinical and support staff). For each Health Board (and for each prison, where applicable), please provide: • Staff grade / staff group (e.g. Band 5 Nurse, GP, Healthcare Assistant, AHP, etc.) • Whole Time Equivalent (WTE) • Total workforce cost attributable to that grade or staff group Please provide the information for the most recent full financial year available (e.g. 2025–26). If finalised figures are not yet available, please provide the latest estimated outturn and indicate this in your response.
Date of Response: 11/05/2026
View Response: 11393.pdf
Freedom of Information Request Reference: 11391
Date Received: 14/04/2026
Summary:
Requested information – Part 1 I would like to request the following information about test turnaround times for your three most recent reporting years: 1. The definition of test turnaround time you use for reporting, including key data points (e.g. when you start and stop the clock). 2. The average annual turnaround time for the solid tumour genomic testing that you have performed. 3. How test failures are accounted when calculating the turnaround time for a sample (e.g. do you restart the clock or do allow the clock to continue running). Requested information – Part 2 I would like to request the following information about test failures for your three most recent reporting years: 1. The total number of solid tumour samples received for genomic testing. 2. a) The total number of solid tumour samples that your service received that were of insufficient quality or quantity on receipt for genomic testing and were not tested or were tested using a different method. b) What are the top 3 cancer types associated with QNS issues at sample triage? 3. The total number of solid tumour genomic tests performed. 4. a) The total number of solid tumour genomic tests that were initiated and failed due to sample quality and/or sample quantity issues (exclude re-tests of unique samples). b) What are the top 3 cancer types associated with QNS issues driving test failures?
Date of Response: 11/05/2026
View Response: 11391.pdf
Freedom of Information Request Reference: 11388
Date Received: 13/04/2026
Summary:
My query is in relation to patients who receive kidney dialysis at home, specifically the health board's policy of reimbursing energy costs to those patients. 1. Does your health board offer reimbursement for the energy costs of patients receiving i) home haemodialysis and ii) home automated peritoneal dialysis (APD)? 2. What is the current rate of reimbursement for patients receiving i) home haemodialysis and ii) home automated peritoneal (APD) dialysis? 3. Does your health board reimburse patients for the cost of heating the room in which home dialysis is received? 4. Does your health board have a set policy of home dialysis reimbursement for patients which is available to them or placed in the public domain?
Date of Response: 11/05/2026
View Response: 11388.pdf
Freedom of Information Request Reference: 11387
Date Received: 13/04/2026
Summary:
1. Service existence and configuration (a) Does your NHS body host, or directly provide a dedicated headache and/or migraine service/clinic? If yes, please specify whether it is: dedicated headache clinic; migraine clinic; neurology clinic with dedicated headache sessions; community service; or other (please describe). (b) Please provide the service name(s), provider organisation(s)/site(s), and patient group(s) served (adult, paediatric, or both). 2. Named clinical/service lead (a) Please provide the name, job title, and employing organisation of the current named clinical/service lead for the headache/migraine service/pathway. (b) If there is no single named lead, please provide the name(s) and title(s) of the most senior clinician(s) responsible for headache/migraine care/pathway governance. 3. Workforce size (headcount and WTE) For the most recent 12-month period available (or the latest point-in-time establishment), please provide the staffing complement allocated to the headache/migraine service/pathway, broken down as follows: (a) Nurses (including headache specialist nurses/ANPs) – headcount and WTE, and banding (e.g., Agenda for Change band) if recorded. (b) Pharmacists (clinical pharmacists, prescribing pharmacists, medicines optimisation) – headcount and WTE, and banding/grade if recorded. (c) Administrative/clerical staff – headcount and WTE, and banding/grade if recorded. (d) Any other staff groups materially involved in the service (optional but helpful): consultants/medical staff, allied health professionals, psychologist, physician associates – headcount and WTE. 4. Service capacity indicators (optional but helpful) (a) Number of headache/migraine clinics/sessions delivered per week or per month (or annual total). (b) Number of new and follow up appointments for headache/migraine in the last 12 months (if recorded). (c) Current waiting time for first appointment (e.g., median or RTT measure used locally) for headache/migraine referrals.
Date of Response: 11/05/2026
View Response: 11387.pdf
Freedom of Information Request Reference: 11385
Date Received: 09/04/2026
Summary:
Please provide information relating to dementia post diagnostic services within your NHS Board area. Specifically, I would be grateful if you could advise on the following: 1. Post diagnostic service provision o Does your NHS Board provide a post diagnostic service (PDS) for people with dementia? o If yes, is this service provided directly by the NHS Board, commissioned from a third sector organisation, or delivered via a hybrid model? 2. Medication reviews for cholinesterase inhibitors o As part of post diagnostic or related services, does your NHS Board carry out medication reviews for the commencement and ongoing monitoring of acetylcholinesterase inhibitors (e.g. donepezil, rivastigmine, galantamine)? 3. Frequency of reviews o If medication reviews are undertaken, please outline:  The timing/frequency of reviews following initiation (for example at 4 weeks, 12 weeks, or other intervals)  Whether ongoing reviews continue beyond the initial titration period, and if so at what frequency 4. Staffing and professional roles o Please indicate which staff groups undertake these medication reviews, for example:  Registered nurses (and specialty if applicable)  Unregistered nursing staff  Allied Health Professionals (please specify profession)  Medical staff o Where applicable, please indicate whether reviews are undertaken under protocols, patient group directions, or clinical supervision arrangements.
Date of Response: 19/05/2026
View Response: 11385.pdf
Freedom of Information Request Reference: 11384
Date Received: 10/04/2026
Summary:
• Does the Health Board purchase/ use a Chlorehidine based body wash for skin decontamination? • If YES, what brand of Chlorhexidine based body wash has been used in the last 12 months (e.g Hibiwash) ? • Volume : How many units have been used over the latest 12 months? • Spend: what is the latest annual spend on Chlorhexidine body wash ?
Date of Response: 11/05/2026
View Response: 11384.pdf
Freedom of Information Request Reference: 11381
Date Received: 09/04/2026
Summary:
For the past three reporting years, either financial or Jan-Dec, please provide the following; Number of 2222 calls made for each site; WGH, RIE, RHCYP, Royal Edinburgh, DCN and SJH. Then a breakdown of how many 2222 calls are for; - Adult Cardiac Arrest - Paediatric Cardiac Arrest - Adult Medical Emergency - Paediatric Emergency - Obstetrical Emergency - Obstetrical Cardiac Arrest - MHP Activation - Obstetrical MHP Activation - Code Red Trauma Call (RIE ONLY) - Paediatric Trauma Call - 1 or 2 (RHCYP only) Please provide this for per site, year by year for the past three years. For WGH and Royal Edinburgh sites, the number of 999 Emergency Ambulance Calls that were placed NOT for emergency transfers but on site medical emergencies requiring emergency ambulance assistance.
Date of Response: 12/05/2026
View Response: 11381.pdf
Freedom of Information Request Reference: 11378
Date Received: 08/04/2026
Summary:
Section 1: Department details 1. Type of department • Paediatric ED • Mixed ED with paediatric area • General ED seeing children • Minor injury unit or urgent treatment centre • Other 2. Does your department have a written local guideline for paediatric upper limb fractures? • Yes • No • Unsure If Yes - would you be able to share it please with us? 3. Which guidance most strongly informs local practice for your paediatric patients? • NICE (National institute of Clinical Excellence) • BOAST ( British Orthopaedic Association) • BSCOS ( British society of Children’s orthopaedics) template or local adaptation • Local orthopaedic guideline • Local Emergency Department guideline • Other 4. Is a virtual fracture clinic available for paediatric fractures? • Yes • No • Only for selected fracture types - could you specified which ones please? 5. Are written discharge leaflets routinely given for paediatric fractures? • Always • Usually • Sometimes • Never For each of the following fractures for each of your departments could you answer the questions for your paediatric patients? Clavicular fracture (uncomplicated closed midshaft clavicle fracture) 1. Usual immobilisation • No immobilisation • Broad arm sling • Collar and cuff • Figure-of-8 brace • Other 2. Usual follow-up • No routine follow-up • Virtual fracture clinic • Face-to-face fracture clinic • Orthopaedic clinic only if adolescent or displaced • Other 3. Is orthopaedic discussion routinely required from ED? • No • Only if significantly displaced, skin compromise, open fracture, or neurovascular concern • Yes for most clavicle fractures • Other Closed Supracondylar humerus fracture 1. Gartland I or radiologically occult but clinically suspicious supracondylar injury: usual immobilisation • Collar and cuff • Posterior backslab • Above-elbow cast • Other 2. Gartland I: usual follow-up • No routine follow-up • Virtual fracture clinic • Face-to-face fracture clinic • Other 3. Gartland II or III: usual first ED step • Backslab and refer orthopaedics • Immediate orthopaedic review in ED • Admit under orthopaedics • Transfer to another centre • Other 4. For Gartland II or III injuries, is reduction or manipulation attempted in ED before theatre or admission? • Never • Occasionally in selected cases • Usually • Unsure 5. Is neurovascular status formally documented before and after immobilisation or reduction? • Always • Usually • Sometimes • Never Lateral closed condyle fracture 1. Undisplaced lateral condyle fracture: usual ED immobilisation • Backslab • Above-elbow cast • Sling only • Other 2. Undisplaced lateral condyle fracture: usual follow-up • Face-to-face fracture clinic within 1 week • Virtual fracture clinic • No routine follow-up • Other 3. Displaced or uncertain lateral condyle fracture: usual ED pathway • Backslab and orthopaedic discussion • Immediate orthopaedic review • Admit or transfer • Other Radial neck or radial head fracture 1. Undisplaced or minimally angulated fracture: usual immobilisation • Collar and cuff • Broad arm sling • Backslab • Other 2. Undisplaced or minimally angulated fracture: usual follow-up • No routine follow-up • Virtual fracture clinic • Face-to-face fracture clinic • Other 3. For more displaced or intra-articular injuries, what is the usual ED pathway? • Orthopaedic discussion then discharge in immobilisation • Admit under orthopaedics • Transfer to another centre • Other Buckle fractures 1. Usual immobilisation • No immobilisation • Soft bandage • Removable wrist splint • Soft cast or backslab • Circumferential cast • Other 2. Is the child usually discharged from ED with no planned follow-up? • Yes • No • Depends on clinician • Unsure 3. If follow-up is arranged, what is usual? • No follow-up • Virtual fracture clinic • Face-to-face fracture clinic • GP follow-up • Other 4. Are parents or carers advised to remove immobilisation at home? • Yes • No • Depends on device used 5. Is a written buckle fracture advice leaflet routinely given? • Always • Usually • Sometimes • Never Distal radius greenstick or undisplaced metaphyseal fracture 1. Usual immobilisation • Removable wrist splint • Below-elbow backslab or soft cast • Below-elbow full cast • Above-elbow cast • Other 2. Usual follow-up • No routine follow-up • Virtual fracture clinic • Face-to-face fracture clinic • Other 3. Is home removal of immobilisation routinely advised? • Yes • No • Depends on fracture pattern Distal radius closed displaced fracture or distal radial physeal injury 1. If reduction is required, is this usually attempted in ED? • Yes, usually • Yes, in selected cases only • No, usually managed by orthopaedics after admission • Unsure 2. Post-reduction immobilisation • Below-elbow backslab • Below-elbow full cast • Above-elbow backslab • Above-elbow full cast • Other 3. Usual follow-up • Virtual fracture clinic • Face-to-face fracture clinic within 1 week • Admit under orthopaedics • Other
Date of Response: 01/06/2026
View Response: 11378.pdf
Freedom of Information Request Reference: 11361
Date Received: 02/04/2026
Summary:
Q1. How many patients have been treated (for any condition) in the last 4 months with: •Benralizumab •Dupilumab •Omalizumab •Reslizumab •Mepolizumab •Tezepelumab Q2. How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with: •Dupilumab •Omalizumab Q3. How many patients have been treated in the last 4 months for Chronic Obstructive Pulmonary Disease (COPD) with: •Dupilumab •Mepolizumab
Date of Response: 01/05/2026
View Response: 11361.pdf
Freedom of Information Request Reference: 11360
Date Received: 02/04/2026
Summary:
Details of all notes of interest in and applications for inclusion in the pharmaceutical list (i.e. applications to open a new Pharmacy). Details to include: 1. Date note of interest / application received 2. Area which note of interest / application relates to 3. Address of note of interest / application if possible 5. Position in queue of expressions of interest in relation to: A) The Health Board overall queue B) The queue for that specific area / neighbourhood. 6. Status of the expression of interest e.g at Pre-Application Stage, Pre-Application process complete, At Joint Consultation stage, Joint Consultation complete or Application submitted.
Date of Response: 13/05/2026
View Response: 11360.pdf
Freedom of Information Request Reference: 11355
Date Received: 26/03/2026
Summary:
In several FOI requests there are references that a ADHD diagnosis may be expedated due to comorbid mental health and or receiving a diagnosis of ADHD without having to get an assessment. What would be the actual process of expediting an ADHD assessment in West Lothian?
Date of Response: 13/05/2026
View Response: 11355.pdf
Freedom of Information Request Reference: 11345
Date Received: 30/03/2026
Summary:
I would like to request access to the following de-identified, patient data from this hospital: 1. Number of patients treated for Achilles tendon rupture over the past 10 years 2. Tendon length measurements at approximately 6 weeks post-injury (mean ± SD, or ranges) 3. Time to return to sport or activity (mean ± SD, or ranges) 4. Relevant patient variables to adjust for potential confounders, including: o Age o Sex o Type of surgical repair (open, percutaneous, augmented) o Rehabilitation protocol (standard vs accelerated) o Co-morbidities
Date of Response: 19/05/2026
View Response: 11345.pdf
Freedom of Information Request Reference: 11340
Date Received: 25/03/2026
Summary:
I wonder if I can ask some questions about the Meningitis B Vaccine as I have had a number of people in touch with various questions: • Please can you tell me what the strategy is to protect students and children in Scotland? • Can you tell me where my teenage children can get vaccinated? • People need two shots a month apart to gain full protection so if there rapid rollout planned to save lives? • Are there plans to ensure students can be given antibiotics quickly should the strain reach Scotland? • I need to know where students returning to University can get the vaccine
Date of Response: 13/05/2026
View Response: 11340.pdf
Freedom of Information Request Reference: 11325
Date Received: 23/03/2026
Summary:
1. The number of racial discrimination or racial abuse incidents reported by nursing staff in your NHS Board broken down by each full calendar year 2022, 2023, 2024 and 2025, from: a) patients, b) patient’s relatives c) the public,  d) in total (from patients, relatives and the public) 2. The number of racial discrimination or racial abuse incidents reported by nursing staff from patients, relatives or members of the public in your NHS Board broken down by each full calendar year 2022, 2023, 2024 and 2025, by ethnic group of member of nursing staff. Please categorise the incidents by the main ethnic groups recorded in eESS – African, Asian, Caribbean or Black, White, Mixed or multiple ethnic group, Other ethnic group, Declined, Not Known. 3. What anti-discrimination actions has the Board taken as a result of the data indicating that they have staff that have been racially abused?
Date of Response: 13/05/2026
View Response: 11325.pdf
Freedom of Information Request Reference: 11315
Date Received: 19/03/2026
Summary:
1. The number of compensation payouts made by NHS Lothian in the last six financial years starting in 2019/2020, inclusive. 2. Please specify whether each payout was made to an employee or member of the public under the care of NHS Lothian. a. In the case of an employee, please provide the job title of the employee (including but not limited to doctor, nurse, cleaner, executive, etc.) 3. Please specify the amount of compensation paid per case in pounds sterling. Please also provide the total amount of all cases during the overall time period. 4. Please specify the reason for the compensation paid per case (such as vehicle accident claims, employer liability and employment tribunal, public liability claims, etc.) 5. Please specify if the claim concerned a specific site or organisation, such as the Scottish Ambulance Service, Royal Infirmary of Edinburgh, St John's Hospital, etc.
Date of Response: 13/05/2026
View Response: 11315.pdf
Freedom of Information Request Reference: 11280
Date Received: 10/03/2026
Summary:
For the financial years 2021/22, 2022/23, and 2023/24 (to the most recent month for which data is available), please provide: 1. A dataset detailing: a. The total annual expenditure on temporary agency staff, broken down by staff role or category (e.g., nurse, doctor, allied health professional, admin, etc.). b. The number of shifts filled by agency staff, by occupational category and by month. 2. Copies of all contracts and service level agreements signed with third-party recruitment agencies or staffing firms for supplying temporary or locum staff, including terms and conditions, fee structures, and expiry dates. 3. The most recent internal reports, audits, or assessments produced concerning: a. The impact of agency staff expenditure on NHS Lothian’s budget and financial planning. b. Strategies to reduce reliance on agency workers, or rationales for continued usage. 4. All procurement evaluation documents, tender award summaries, and scoring criteria used for selecting and renewing contracts with recruitment or staffing agencies since January 2021. 5. Minutes and agenda papers from any Board meetings, executive team meetings, or subcommittees (including but not limited to Finance, Staffing, or Workforce committees) from January 2022 onwards, where the use of or spending on agency staff, or relevant contracts, were discussed. 6. Copies of all internal communications (including but not limited to emails, memos, or briefings) from January 2022 to the present between: a. NHS Lothian executives/directors and heads of departments on the subject of temporary agency staff, recruitment agency selection, or related expenditure. b. NHS Lothian and any external staffing agencies regarding contract changes, pricing negotiations, or concerns about service provision. 7. Any policy reviews, briefing papers, or guidance documents prepared internally or received from NHS Scotland or the Scottish Government since January 2022, relating to agency staff usage, procurement, or cost-control. 8. The financial records and summary breakdowns that show agency staffing expenditure versus spend on permanent staff for the three financial years specified above.
Date of Response: 13/05/2026
View Response: 11280.pdf
Freedom of Information Request Reference: 11273
Date Received: 09/03/2026
Summary:
premises service level agreement between NHS Lothian and the respective GP partnerships: Carmondean Health Centre • Barclay Medical Practice/Carmondean • Carmondean Medical Group Craigshill Health Centre • The Craigshill Partnership Dedridge Health Centre • Dedridge Medical Group East Calder Health Centre • East Calder Medical Practice Fauldhouse Health Centre (Fauldhouse Partnership Centre) • Barclay Medical Practice/Fauldhouse Howden Health Centre • Howden Medical Group Murieston Health Centre (privately owned) • Murieston Medical Practice LLP West Calder Medical Centre • West Calder Medical Practice Can you please provide the following information for any of the above GP practices that are subject to a premises Service Level Agreement with NHS Lothian? 1. Annual SLA premises costs for each GP Practice for year 205/26 2. Projected (or expected) SLA premises costs for year 2026/27 3. Year on year costs rises (if any) expressed in cash and percentage terms
Date of Response: 28/05/2026
View Response: 11273.pdf
Freedom of Information Request Reference: 11205
Date Received: 23/02/2026
Summary:
Please provide details of the Willow Centre's policy on providing a service to men who identify as women and please provide data on the number of men who identify as women who have used the services of the centre over the last five years.
Date of Response: 13/05/2026
View Response: 11205.pdf
Freedom of Information Request Reference: 11190
Date Received: 17/02/2026
Summary:
Will NHS Lothian which includes the East Lothian Health and Social Care Partnership please provide the following information for the period, 1st January 2025 to 31st December 2025:- 1. the number of stage two complaints which it received about any Sexual Health Clinic including any service provided by any Sexual Health Clinic in its management, 2. the number of those stage two complaints referred to in clause (i) above which received a full and final adjudication within twenty working days as required by NHS Lothian's Complaints' Procedure.
Date of Response: 13/05/2026
View Response: 11190.pdf
Freedom of Information Request Reference: 11175
Date Received: 17/02/2026
Summary:
I am writing to request an internal review of Lothian NHS Board's handling of my FOI request 'Corporate Management Team imatter Report'. In your response, you state that there is no report or action plan relating to the CMT as it is “not a team for iMatter purposes”. I would ask that this interpretation is reconsidered. My request was intended to capture whichever senior leadership grouping the Chief Executive’s direct reports were included within for iMatter purposes during the relevant period. If the term “CMT” has been interpreted too narrowly, I would be grateful if the request could instead be applied to the appropriate equivalent team or reporting structure. I also note the reliance placed on the nationally agreed iMatter governance model and confidentiality arrangements. While I recognise the sensitivities of staff experience data, staff governance arrangements do not override statutory obligations under Freedom of Information or data protection legislation. Where information is held, consideration should instead be given to appropriate disclosure, including redaction or anonymisation where necessary, rather than refusal in principle. In addition, the application of section 12 (cost of compliance) would benefit from further clarification. It is not clear from the response what steps were taken to determine whether relevant information is already held in recorded form, nor whether partial disclosure within cost limits was considered.
Date of Response: 01/06/2026
View Response: 11175.pdf
Freedom of Information Request Reference: 10934
Date Received: 10/12/2025
Summary:
In the last 6 months (June 25- November 25), please confirm if any Mental Health services have been outsourced: If yes, please confirm: -The service provided E.G ADHD, Autism etc (please provide breakdown for each service if applicable) -The name of the company each service was outsourced to -Is there a contract in place and the length of contract for each service provided (if applicable) -The value of each service in the last 6 months Please confirm how this contract was procured E.G Tender, Direct Award etc Please provide an email and contact name within the outsource provider
Date of Response: 11/05/2026
View Response: 10934.pdf
Freedom of Information Request Reference: 11416
Date Received: 22/04/2026
Summary:
Request in relation to personal information.
Date of Response: 23/04/2026
View Response: 11416.pdf
Freedom of Information Request Reference: 11407
Date Received: 20/04/2026
Summary:
Request in relation to personal information.
Date of Response: 21/04/2026
View Response: 11407.pdf
Freedom of Information Request Reference: 11394
Date Received: 15/04/2026
Summary:
1. What are the current costs of running the Loanesk Ward in Midlothian Community Hospital with 16 beds 2. What will be the savings created by reducing the number of beds to 10 and relocating the palliative care unit to the rehabilitation ward 3. What will happen to the patients currently using the rehabilitation ward 4. What will be the costs of maintaining rehab care elsewhere and will this represent a saving or an increase in costs for this service?
Date of Response: 07/05/2026
View Response: 11394.pdf
Freedom of Information Request Reference: 11389
Date Received: 13/04/2026
Summary:
Q1. How many patients has your Trust treated (for any medical condition) in the past 3 months with the following drugs: •Alprolix •BeneFIX •Haemate P •Idelvion •Refixia •Rixubis •Veyvondi •Voncento •Wilate •Willfact Q2. How many patients have been treated in the past 3 months with: •Marstacimab for Haemophilia B ONLY •Hemgenix for Haemophilia B ONLY •Desmopressin for Von Willebrand Disease ONLY •Tranexamic Acid for Von Willebrand Disease ONLY Q3. Of the patients that were treated with Veyvondi in the past 3 months, how many patients received treatment: •Prophylactically •During surgery •On demand to treat bleeding episodes Q4. Of the patients that were treated with Voncento in the past 3 months, how many patients received treatment: •Prophylactically •During surgery •On demand to treat bleeding episodes Q5. How many patients are registered with your trust for the following diseases: •Haemophilia B •Von Willebrand Disease •Von Willebrand Disease - paediatric patients (age 17 or under)
Date of Response: 06/05/2026
View Response: 11389.pdf
Freedom of Information Request Reference: 11386
Date Received: 13/04/2026
Summary:
1. Is Basic Life Support course mandatory for the medical professionals working for the Health Board? 2. How many courses per year does your Resus Training Department deliver? 3. What percentage of doctors/nurses/midwives and other allied health professionals have done BLS training in the last 1 year? 4. What percentage of your medical personnel have profession specific Advanced Life Support (ALS) training? 5. What is the required frequency for mandatory BLS training? 6. What strategies or measures has the trust adopted to encourage annual BLS training for medical professionals with patient facing duties ( no pay progression if mandatory training not completed, departmental sessions, ESR alerts, managerial supervision of mandatory training etc)? 7. Does the organisation require resus teams to have Advanced Life Support training?
Date of Response: 04/05/2026
View Response: 11386.pdf
Freedom of Information Request Reference: 11383
Date Received: 10/04/2026
Summary:
From 1st January 2026 to 31st March 2026 please provide a breakdown of: • Total trust spend with framework agencies for locum AHP/HSS staffing. Please provide a further breakdown for locum AHP/HSS staffing by: • Spend per band • Spend per specialty • Spend per agency name In the period 1st January 2026 to 31st March 2026 please provide a breakdown of: • Total trust spend with off-framework agencies for locum AHP/HSS staffing. Please provide a further breakdown for locum AHP/HSS staffing by: • Spend per band • Spend per specialty • Spend per agency name In the period 1st January 2026 to 31st March 2026 please provide a breakdown of: • Total trust spend with the internal trust bank or associated external provider for locum AHP/HSS staffing Please provide a further breakdown for locum AHP/HSS staffing by: • Spend per grade • Spend per specialty • Spend per internal or associated external provider Please confirm your allocated budget for agency locum AHP/HSS staffing for the period 1st January 2026 to 31st March 2026 Please confirm the framework you utilise for AHP/HSS agency staff.
Date of Response: 06/05/2026
View Response: 11383.pdf
Freedom of Information Request Reference: 11382
Date Received: 09/04/2026
Summary:
Q1. Within your trust, how many patients currently have a diagnosis for: •Fabry(-Anderson) disease (ICD10 code E75.21) •Gaucher disease (ICD10 code E75.22) •Pompe disease (ICD10 Code E74.02) •Pompe disease (ICD10 Code E74.02) infantile onset (patients diagnosed before age 1) •Hunter syndrome (MPS II) (ICD10 code E76.1) Q2. Of the patients above, how many patients have been newly diagnosed within the past 3 months for: •Fabry(-Anderson) disease (ICD10 code E75.21) •Gaucher disease (ICD10 code E75.22) •Pompe disease (ICD10 Code E74.02) •Pompe disease (ICD10 Code E74.02) infantile onset (patients diagnosed before age 1) •Hunter syndrome (MPS II) (ICD10 code E76.1) Q3. How many patients have been treated in the last 3 months with the following products: •Replagal (agalsidase alfa) •Fabrazyme (agalsidase beta) •Galafold (migalastat) •Elfabrio (pegunigalsidase alfa) •VPRIV (velaglucerase alfa) •Cerezyme (imiglucerase) •Cerdelga (eliglustat) •Zavesca (miglustat) •Myozyme (alglucosidase alfa) •Nexviadyme (avalglucosidase alfa) •Pombiliti + Opfolda (cipaglucosidase alfa + miglustat) Q4. Do you participate in any clinical trials for Fabry(-Anderson) disease? If so, can you please provide the name of each trial along with the number of patients taking part? Q5. Do you participate in any clinical trials for Gaucher disease? If so, can you please provide the name of each trial along with the number of patients taking part?
Date of Response: 06/05/2026
View Response: 11382.pdf
Freedom of Information Request Reference: 11380
Date Received: 09/04/2026
Summary:
From January 2024-March 2026, how many candidates who applied for NHS Lothian jobs under the Guaranteed Interview Scheme set out by the UK Government, were offered an interview?
Date of Response: 06/05/2026
View Response: 11380.pdf
Freedom of Information Request Reference: 11377
Date Received: 08/04/2026
Summary:
I am requesting aggregated information about brain tumour resections carried out by your Trust and whether resected brain tumour tissue can be flash frozen to -80°C within 30 minutes of resection. Time period: Please provide the information below for the two most recent full years for which data is available. Definition: “Fresh-frozen” means brain tumour tissue that is snap frozen and stored at -80°C or colder. Questions: 1. Does your Trust perform neurosurgical brain tumour surgery or biopsy on-site? (Yes/No) 2. For patients undergoing brain tumour surgery or biopsy under your Trust’s care, does the usual clinical pathway provide access to facilities that place brain tumour tissue into a fresh-frozen state within at least 30 minutes of excision? (Yes / No / Not applicable) 3. If Yes, is this access: a) On-site within your Trust b) Off-site/external c) Both 4. If off-site/external, please name the organisation or type of facility used. 5. For each year, approximately how many patients underwent surgery or biopsy for a brain tumour / brain cancer at your Trust? 6. For each year, approximately how many brain tumour tissue specimens were handled by your pathology service? 7. For each year, how many of these specimens were fresh-frozen: a) within any time frame? b) within 30 minutes?
Date of Response: 06/05/2026
View Response: 11377.pdf
Freedom of Information Request Reference: 11376
Date Received: 08/04/2026
Summary:
Q1. How many haemophilia A patients are registered with your centre, and how many of these patients are classified as exhibiting mild, moderate, or severe disease. Q2. In the last three months, how many Haemophilia A patients, including on-demand patients, have been treated with the following products? •Altuvoct •Advate •Adynovi •Elocta •Esperoct •Factor Eight Inhibitor Bypass Activity (FEIBA) •Hemlibra (standalone) •Hemlibra in combination with any Factor VIII •NovoEight •NovoSeven RT •Nuwiq •Obizur •Refacto AF •Any other products •Marstacimab •Cevenfacta Q3. For patients treated with Advate in the last three months, please provide: •The number of haemophilia A patients treated prophylactically •The number of haemophilia A patients treated for any other reason (e.g. surgery, on-demand, breakthrough bleeds) Q4. In the last three months, how many patients were treated with the following products for severe Haemophila A ONLY? •Altuvoct •Advate •Adynovi •Elocta •Esperoct •Factor Eight Inhibitor Bypass Activity (FEIBA) •Hemlibra (standalone) •Hemlibra in combination with any Factor VIII •NovoEight •NovoSeven RT •Nuwiq •Obizur •Refacto AF •Any other products •Marstacimab •Cevenfacta
Date of Response: 05/05/2026
View Response: 11376.pdf
Freedom of Information Request Reference: 11374
Date Received: 07/04/2026
Summary:
Please can we request freedom of information for the amputation figures across Scotland. If we can have it broken down by region and also type for instance particularly interested in leg, arm, hand, foot amputations. If we can have figures for the past 3 years that would be most helpful.
Date of Response: 01/05/2026
View Response: 11374.pdf
Freedom of Information Request Reference: 11372
Date Received: 01/04/2026
Summary:
Question 1. How many patients were treated in the last 4 months (December to March 2026) by the dermatology department with each of the following products: •Abrocitinib •Acitretin •Alitretinoin •Azathioprine •Baricitinib •Ciclosporin •Dupilumab •Lebrikizumab •Methotrexate •Mycophenolate mofetil •Pimecrolimus •Phototherapy (UVB or PUVA) - for Atopic Dermatitis only •Tacrolimus ointment •Tralokinumab •Upadacitinib •Nemolizumab Question 2. In the last 4 months, how many new patients have been initiated* on the following treatments by the dermatology department •Abrocitinib •Baricitinib •Dupilumab •Lebrikizumab •Tralokinumab •Upadacitinib •Nemolizumab *Patients are considered ‘new patients initiated’ on a treatment if they have not been previously treated with any of the other named treatments above since 1st April 2025 prior to initiation. e.g. Patient initiated on Lebrikizumab in Dec 2025 - March 2026 (has not previously been treated with Abro, Bari, Dupi, Tralo, Upada, Nemo since March 2025) Question 3. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group: •6 months to 5 •Age 6-11 •Age 12-17 •Age 18 and above Question 4. How many patients have received treatment by the dermatology department for Prurigo Nodularis in the last 4 months with each of the following products: •Dupilumab •Nemolizumab
Date of Response: 01/05/2026
View Response: 11372.pdf
Freedom of Information Request Reference: 11371
Date Received: 01/04/2026
Summary:
In the period 1st January 2026 to 31st March 2026 please provide a breakdown of: • Total trust spend with framework agencies for locum nurses Please provide a further breakdown for locum nurses by: • Spend per band • Spend per specialty • Spend per agency name In the period 1st January 2026 to 31st March 2026 please provide a breakdown of: • Total trust spend with off framework agencies for locum nurses Please provide a further breakdown for locum nurses by: • Spend per band • Spend per specialty • Spend per agency name In the period 1st January 2026 to 31st March 2026 please provide a breakdown of: • Total trust spend with the internal trust bank or associated external provider for locum nurses Please provide a further breakdown for locum nurses by: • Spend per band • Spend per specialty • Spend per agency name Please confirm the total number of nursing shifts booked during this period for all agency nursing only, no bank staff nursing to be included (1st January 2026 to 31st March 2026) Please confirm the total number of nursing shifts booked above NHSE capped rates during this period for all agency nursing only, no bank staff nursing to be included (1st January 2026 to 31st March 2026) Please confirm the framework you utilise for nursing agency staff.
Date of Response: 01/05/2026
View Response: 11371.pdf
Freedom of Information Request Reference: 11369
Date Received: 01/04/2026
Summary:
Please provide the following recorded information relating to NHS-commissioned complex care at home and specialist community nursing services: 1. Total expenditure on complex care packages delivered at home (including NHS Continuing Healthcare (CHC) and non-CHC complex community health packages) for each of the last three full financial years and the current year to date. Please separate adults and children where the data is held. 2. The number of active complex care packages at home as at the most recent date available, broken down by: o Adults / Children o Broad clinical category where held (e.g. learning disabilities/autism, mental health, tracheostomy/ventilation/airway management, other clinically complex needs) 3. A list of all independent, private or voluntary sector providers commissioned for complex care at home or specialist community nursing packages in the period, including (where recorded): o Number of packages per provider o Approximate total spend per provider (or top 10 providers by value) o Whether provision was via full managed package, spot purchase, framework agreement, or rapid-response/temporary staffing 4. Details of any current framework agreements, block contracts or dynamic purchasing systems for complex home care / specialist nursing / rapid-response staffing, including: o Provider names o Contract start and end dates (or review/renewal dates) o Scope (e.g. 24/7 nursing, paediatric, LD/autism/MH, hospital discharge support) 5. The name, job title and contact details (email/telephone) of the commissioner or team lead responsible for sourcing complex care at home packages and rapid-response nursing support.
Date of Response: 30/04/2026
View Response: 11369.pdf
Freedom of Information Request Reference: 11368
Date Received: 30/03/2026
Summary:
For the last five calendar years (or the most recent five year period for which data is available): 1. The number of attendances at any of your emergency and urgent care services (including A&E, Emergency Department, Minor Injuries Unit and Urgent Treatment Centre) where the primary reason for attendance was a ring stuck on a finger. 2. For the attendances identified in Question 1, please provide a breakdown by: • Sex (male / female / other / unknown). • Age group (for example: 0–9, 10–19, 20–29, 30–39, 40–49, 50–59, 60–69, 70+), or whatever age banding you use in your reporting.
Date of Response: 29/04/2026
View Response: 11368.pdf
Freedom of Information Request Reference: 11367
Date Received: 07/04/2026
Summary:
Please confirm if you operate a vendor management system for agency staff such as an MSP/neutral vendor/master vendor etc. If so, please can you name the below: -Company name -Contract start and end date -Framework utilised -Healthcare specialty used for, EG Doctors/Nursing/AHP/HSS/NMNC -Do you utilise a direct engagement model and the name of the model, eg Tempre/Own DE model etc Please confirm if you operate a vendor management system for bank staff. If so, please can you name the below: -Company name -Contract start and end date -Framework utilised -Healthcare specialty used for, EG Doctors/Nursing/AHP/HSS/NMNC
Date of Response: 30/04/2026
View Response: 11367.pdf
Freedom of Information Request Reference: 11366
Date Received: 07/04/2026
Summary:
I request the following information for adult combined ADHD/ASD neurodevelopmental assessments in NHS Lothian for the most recent 24 months: 1. Referral Numbers & Waiting Times o Total number of adult referrals for combined ADHD/ASD assessment. o Median, average, and longest waiting times from referral to assessment, broken down by HSCP area:  Edinburgh City  East Lothian  Midlothian  West Lothian 2. Urgent / Fast-Track Pathways o Number of adults assessed via urgent or fast-track pathways, if any. o Criteria used for prioritisation. 3. Community Team Involvement o Number of adults under Community Mental Health Teams (CMHTs) or Community Parental Mental Health Teams while awaiting assessment. o Average length of involvement while waiting. 4. Shared Care Prescribing Arrangements o Number of adults under shared care agreements for ADHD medication initiated or continued in the past 24 months. o Any delays in medication initiation attributable to waiting for the combined assessment. 5. Cross-Board Referrals o Number of adult referrals received from or sent to other NHS boards (East, West, Borders, Fife, etc.). o Waiting times for these out-of-board referrals. 6. Supporting Documentation o Copies of any internal reports, guidance, or policy documents summarising adult combined ADHD/ASD assessment pathways, waiting lists, or triage procedures in NHS Lothian.
Date of Response: 04/05/2026
View Response: 11366.pdf
Freedom of Information Request Reference: 11363
Date Received: 07/04/2026
Summary:
• The number of emergency: o CT Angio Aorta o CT Angio Aortic Arch and Carotids o CT Aorta Thoracic o CT Aorta Thoracic with contrast o CT Aorta Whole o CT Aorta Whole with contrast • Carried out each year between 1.1.16 and 31.12.25 • To avoid double counting, please identify by Count of Unique Accession Number or equivalent • The number of patients with a primary or secondary ICD-10 diagnosis of I-71.0 discharged dead each year between 1.1.16 and 31.12.25 with an emergency inpatient admission (Please do not include A&E discharge diagnosis). • The number of patients with a primary or secondary ICD-10 diagnosis of I-71.0 discharged dead each year between 1.1.16 and 31.12.25. All patients (Please do not include A&E discharge diagnosis)
Date of Response: 30/04/2026
View Response: 11363.pdf
Freedom of Information Request Reference: 11359
Date Received: 02/04/2026
Summary:
I was looking to make an FOI request regarding the number of elective operations cancelled at Royal Infirmary of Edinburgh due to transplant activity taking priority with the date raging from both 2024-2025 and 2025-2026. A further request is NHS Lothian's estimated running costs to run a single operating theatre for a 24 hour period that is considered fully staffed.
Date of Response: 01/05/2026
View Response: 11359.pdf
Freedom of Information Request Reference: 11358
Date Received: 01/04/2026
Summary:
I am seeking information regarding instances where the wrong person's body was released to families, funeral directors or undertakers. Please tell how many such cases there have been within the health board area since the year 2020. Please provide the relevant hospitals' names, the date of the incidents and the deceaseds' ages. Please also tell me how many complaints the health board has received regarding these matters over the time period.
Date of Response: 01/05/2026
View Response: 11358.pdf
Freedom of Information Request Reference: 11357
Date Received: 01/04/2026
Summary:
Please provide the following information for NHS Lothian services within the West Lothian area: 1. The number of delayed discharges where housing was a factor. 2. The average delay length. 3. The longest delay recorded I request that all information covers the period from 1 January 2025 to the present, and is provided in an electronic tabular format.
Date of Response: 01/05/2026
View Response: 11357.pdf
Freedom of Information Request Reference: 11356
Date Received: 27/03/2026
Summary:
With 2027 just 9 months away and Ferryfield not fit for purpose, what plans have NHS Lothian made to relocate the extremely vulnerable and complex patients currently cared for within the HBCCC unit? I would like to see all documents relating to this matter in the period from July 2023 to present.
Date of Response: 07/05/2026
View Response: 11356.pdf
Freedom of Information Request Reference: 11354
Date Received: 26/03/2026
Summary:
Does your NHS Board provide any mental health services for under 18 year olds (e.g. CAMHS)? If you do not, please reply stating that you do not provide mental health services for under 18 year olds and none of the other questions of this FOI are required as they are not relevant. If you do provide mental health services for under 18 year olds: • What is the age brackets for the mental health services for young people before they move to adult services (for example 0-18 year olds or 0-25 years old)? • What do you call this service (for example Child and Adolescent Mental Health Services (CAMHS) or if there is a specific name you use)? • What methods of referral do you accept (for example- referrals from GPs/schools)? • Are self referrals an option? If so what are the requirements (e.g. minimum age)? • What is your method of advising patients of appointments (e.g. text/post)? I would also like to request a blank document of the following forms: • The form used by GPs/schools to refer a young person • The form used if a young person is referring themselves • Any forms that are provided at the first appointment for the young person/parent to fill out in regards to contact information, preferences of methods of contact, who is attending the appointments etc • Any relevant forms to indicate who is attending the appointment/aware of the referral (young person/their guardian/both) and which of the two should be contacted and if there is a preference of contact method
Date of Response: 06/05/2026
View Response: 11354.pdf
Freedom of Information Request Reference: 11352
Date Received: 30/03/2026
Summary:
I would be grateful if you could provide figures for the number of inpatient / outpatient / day case appointments and any other NHS activity measurements that are available for: (a) June 15 last year (b) The May 5 bank holiday last year (c) The May 26 bank holiday last year
Date of Response: 29/04/2026
View Response: 11352.pdf
Freedom of Information Request Reference: 11351
Date Received: 25/03/2026
Summary:
Beginning from January 1, 2020 until March 25, 2026 I am requesting a breakdown of staff members at four NHS Lothian hospitals who have been suspended, sanctioned, or struck off for sexual misconduct. The four hospitals are the Royal Infirmary of Edinburgh, the Western General Hospital, the Royal Edinburgh, and the Royal Hospital for Children & Young People. Please provide: 1. The date the sanction went into effect 2. The general job title for the staff member (including but not limited to nurse, doctor, technician, administrative assistant, etc) 3. Whether the misconduct was perpetrated against another member of staff, a patient, or a member of the public who was visiting the hospital 4. For those members of staff who were suspended/sanctioned, please note whether they have returned to work at NHS Lothian as of March 25, 2026
Date of Response: 20/04/2026
View Response: 11351.pdf
Freedom of Information Request Reference: 11350
Date Received: 01/04/2026
Summary:
Total number of male nurses employed by you in the past 5 years. Total number of male nurses in each of these fields: Adult Children's Mental Health Learning Disability
Date of Response: 06/05/2026
View Response: 11350.pdf
Freedom of Information Request Reference: 11349
Date Received: 01/04/2026
Summary:
According to this NHS Inform page - Breast screening in Scotland | NHS inform - a woman undergoing a mammogram as part of the national screening programme will: "receive 1 of 3 results: • normal result • positive result • inconclusive result" 1. What criteria were applied in 2020 and 2023 and are applied now by the reporting radiologist to determine whether results are classified as normal, positive or inconclusive? 2. What national or professional guidance/criteria did/does the reporting radiologist refer to when making their determination? 3. If a patient were found to have "indeterminate calcification" on their first mammogram (age 50-53) undertaken during the screening process in September 2020, would this result in a normal, positive or inconclusive report? 4. If a patient were found to have "indeterminate calcification" on their second mammogram (age 53-56) undertaken during the screening process in July 2023, would this result in a normal, positive or inconclusive report? 5. If a patient had received a "positive" result in either September 2020 and/or July 2023, what would then happen have happened?
Date of Response: 29/04/2026
View Response: 11349.pdf
Freedom of Information Request Reference: 11348
Date Received: 01/04/2026
Summary:
For the period from 1 September 2024 to 1 April 2026: 1. Are injectable pharmacological treatments for overweight and obesity currently being initiated for patients as part of routine services commissioned or delivered by your organisation? If so, please identify which medication(s) are currently used as first-line injectable pharmacological therapy for overweight and obesity within commissioned services. 2. What are the eligibility criteria for patients to access injectable pharmacological treatments for overweight and obesity within your organisation? Where these criteria are already published online, please provide the relevant link and confirm whether the published criteria are currently being applied in practice. 3. Please confirm whether the model of care through which these treatments are (or will be) delivered: o Directly from general practice o Primary care-led weight management service (e.g. GP or pharmacist-led weight management service, community weight management hub, etc.) o Tier 3 specialist weight management services o Other (please specify). 4. Please confirm whether the relevant pathway within your organisation is currently: o operational and accepting referrals o operational but limited (e.g. pilot sites) o approved but not yet implemented o currently under development. 5. Please provide copies of any key or current clinical pathways, service specifications, prescribing guidance, or referral criteria relating to the use of injectable pharmacological treatments for overweight and obesity, if held.
Date of Response: 23/04/2026
View Response: 11348.pdf
Freedom of Information Request Reference: 11347
Date Received: 01/04/2026
Summary:
HAE & IG questionnaire HAE: Q1. In the past 3 months [latest 3 months available] how many patients have received the following treatments [for any disease]: Berinert (Human C1-esterase inhibitor) Cinryze (Human C1-esterase inhibitor) Orladeyo (Berotralstat) Takhzyro (Lanadelumab) Ruconest (Recombinant human C1-esterase inhibitor) Firazyr (Icatibant injection) Icatibant - any brand except Firazyr IG: Q2. In the past 3 months how many patients have received the following treatment for any disease: Octagam Gamunex Intratect Kiovig Gamten Panzyga Xembify Cuvitru Cutaquig Hyqvia Q3: In the past 3 months, how many patients have received any immunoglobulin treatment for the following diseases: Primary immunodeficiency (PID) Secondary immunodeficiency (SID) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Date of Response: 23/04/2026
View Response: 11347.pdf
Freedom of Information Request Reference: 11343
Date Received: 25/03/2026
Summary:
I am seeking recorded information relating to your organisation’s decarbonisation and net zero planning, with particular reference to estate energy use and Scope 1 and 2 emissions. 1) Please provide copies of your current decarbonisation, net zero or climate action plans, including any estate specific or heat decarbonisation plans (or equivalent). 2) Please provide any associated implementation plans, project pipelines or delivery road maps, including documents that set out sequencing, timelines or phasing of decarbonisation activity. 3) Please provide details of planned and/or active projects relating to: •Electricity reduction ( Scope 2) •Heat decarbonisation ( Scope 1) •On site renewable generation including where held : •Estimated Capital Cost •Forecast Energy Savings ( kWh) •Forecast Annual Financial Savings (£) •Forecast Annual Carbon savings (tCO₂e) •Estimated Payback Period. 4) Please provide any business cases, option appraisals or prioritisation frameworks used to assess and rank decarbonisation projects. 5) Please provide details of any completed decarbonisation within the last three financial years, including any evaluation of forecast versus actual performance (energy, cost and carbon savings). 6) Please confirm : •Your baseline year for carbon emissions reporting. •Your most recent reported Scope 1 and Scope 2 Emissions •Whether Scope 2 is reported on a location based and/or market-based methodology. 7) Please provide details of governance arrangements for decarbonisation delivery, including committee, board or group responsible for oversight.
Date of Response: 24/04/2026
View Response: 11343.pdf
Freedom of Information Request Reference: 11342
Date Received: 31/03/2026
Summary:
1. How many general practices or within the health board provide respiratory diagnostic tests such as a) spirometry and b) fractional exhaled nitric oxide tests. 2. How many general practices refer patients to community health centres or hubs (excluding secondary care such as hospitals) for respiratory diagnostic tests such as a) spirometry and b) fractional exhaled nitric oxide tests. 3. Name each community health centre or hub that provides respiratory diagnostic tests and list the cluster of general practices that are in the boundary of each centre/hub.
Date of Response: 22/04/2026
View Response: 11342.pdf
Freedom of Information Request Reference: 11341
Date Received: 31/03/2026
Summary:
1. What was the total qualified podiatry workforce in your Health Board on a full time equivalent (FTE) basis on 1st March 2025, including bandings? 2. What was the total qualified podiatry workforce in your Health Board on a full time equivalent (FTE) basis on 1st March 2026? 3. Within the Podiatry department in your Health Board what number of vacancies were there on 1st March 2026, and for which bandings? 4. How many roles within the Podiatry department in your Health Board have been advertised from 1st March 2025 to 1st March 2026, and at which bandings? 5. Within the Podiatry department in your Health Board how many applications did you receive per post advertised between 1st March 2025 to 1st March 2026 6. Within the Podiatry department in your Health Board of the posts advertised between 1st March 2025 to 1st March 2026 how many received no applications? 7. Within the Podiatry department in your Health Board of the posts advertised between 1st March 2025 to 1st March 2026, how many roles were you unable to appoint?  Please give reason, if known. 8. Within the Podiatry department in your Health Board of the posts advertised between 1st March 2025 to 1st March 2026 which banding it is your Health Board having the most difficulty to recruit qualified podiatrists to? 9. How many podiatrists left the Health Board between 1st March 2025 to 1st March 2026 (Please specify WTE and bandings) 10. Of those who left your Health Board between 1st March 2025 to 1st March 2026 specify their reason for leaving i)  Retirement ii) Change of career iii) Private practice iv) Other
Date of Response: 23/04/2026
View Response: 11341.pdf
Freedom of Information Request Reference: 11338
Date Received: 31/03/2026
Summary:
• What is the average wait time for being referred to sleep medicine (or whichever department/team deals with sleep apnoea)? I am under the assumption is 34 weeks for urgent cases, please confirm. What is it for non-urgent cases? • What private sleep clinics do they accept the assessment/diagnosis of? I understand that not all private clinics are accepted by the NHS depending on the condition (such as for ADHD), so I want to find out specifically which ones a patient should go to if they want the NHS to honour the private diagnosis. • If the NHS only accepts certain private clinics' input, how can a patient tell them apart from ones the NHS does not? What is the difference? Why? etc. • If a patient were to go private for part or all of the process, and drop back into the NHS for the remainder of the process, what can the patient expect from that? For example, shorter wait times as it may jump straight to treatment, or it making no difference, or making it harder to get treatment because part of the process was not through NHS, or something else entirely. • What can a patient expect if they do go private for some or all of this process with regards to it tying into the NHS? • Does going private multiple times affect getting NHS care in anyway? Many people seem to be under the impression that if you go private more than once that you are forced to opt out of all NHS care. • I'm also looking for general guidance on going private to help speed up the process
Date of Response: 30/04/2026
View Response: 11338.pdf
Freedom of Information Request Reference: 11337
Date Received: 30/03/2026
Summary:
Could I please get the number of risks identified by the infection control team across the Royal Hospital for Children and Young People over the last five years accompanied with the date identified, if a patient was moved from the room due to the issue identified and by which ward the risk was identified in.
Date of Response: 21/04/2026
View Response: 11337.pdf
Freedom of Information Request Reference: 11336
Date Received: 30/03/2026
Summary:
Please provide responses to the questions below. Programme Existence and Delivery 1. Do you currently operate a Lung Health Check / Lung Cancer Screening programme? 2. Is the programme delivered: o Directly by the NHS, or o By a third party / private sector provider? If so, who? Scanning and Equipment 1. If the programme is delivered directly by the NHS, has CT scanning equipment been purchased to support delivery of the programme? 2. How is CT scanning capacity delivered as part of the programme: o In house, o Via mobile units, or o Via a third party provider? Contractual Information 1. What is the contract start date for the Lung Health Check / Lung Cancer Screening programme? 2. What is the contract end date (or expected end date, if applicable)? 3. Who is the responsible officer or programme director for the programme? Funding 1. What is the total funding allocated to Lung Health Checks / Lung Cancer Screening in your area for the current financial year? 2. What is the source of this funding (for example: NHS England, Integrated Care Board, Cancer Alliance, or other)? Commissioning Responsibility 1. Which organisation is the commissioning body for the programme? o NHS England o Integrated Care Board (ICB) o Cancer Alliance o Other (please specify) Programme Footprint and Delivery Model 1. At what level is the programme commissioned and delivered: o ICB level, o Trust level, o Place / locality level, or o A combination of the above? Future Plans 1. Are there any current plans to expand the programme footprint or change the delivery model within the next 12–24 months? Integrated Screening 1. In light of any recent or planned ICB mergers or footprint changes, are there plans to develop an integrated screening programme (for example, combining lung screening with other screening pathways)?
Date of Response: 21/04/2026
View Response: 11336.pdf
Freedom of Information Request Reference: 11334
Date Received: 27/03/2026
Summary:
1. Please provide the total number of A&E attendances by patients of No Fixed Abode/Address due to heat related illness. Please provide data for the following time periods: •1st July 2025 – 30th September 2025 •1st July 2024 – 30th September 2024 If using SNOMED CT codes, we are interested in the following codes. If you do not use SNOMED CT coding we are happy to be guided by you on the best codes that represent heat related illnesses: •1197782006 | Hyperthermia (disorder) | •52072009 | Heat stroke (disorder) | •18615009 | Sunstroke (disorder) | •95868006 | Heat exhaustion (disorder) | •89797005 | Heat syncope (disorder) | •87108006 | Heat cramp (finding) | •55017000 | Heat edema (disorder) | •12979003 | Transient heat fatigue (disorder) | •70226007 | Heat pyrexia (disorder) | •212937007 | Heat stroke and sunstroke (disorder) |
Date of Response: 27/04/2026
View Response: 11334.pdf
Freedom of Information Request Reference: 11332
Date Received: 26/03/2026
Summary:
Please provide: Any recorded decision, report, minute or approval confirming whether the site, or any part of it, is intended to be sold or otherwise disposed of. Any recorded information showing the key decision points or approvals still required before the site can be marketed or sold. Any recorded information showing whether NHS Lothian is considering applying any conditions, restrictions or obligations to a sale of the site, including any requirements relating to future community, care or healthcare use. Any recorded information showing whether NHS Lothian has entered into or approved any exclusivity arrangement, preferred bidder arrangement, heads of terms, or similar pre-sale agreement with any third party in relation to the site.
Date of Response: 06/05/2026
View Response: 11332.pdf
Freedom of Information Request Reference: 11331
Date Received: 26/03/2026
Summary:
I understand that Surgical Site Infection (SSI) surveillance is conducted nationally in Scotland for specified mandatory procedures, including caesarean section. If possible I'd like to request the following information: •The number of caesarean section procedures performed in NHS Lothian •The number of Surgical Site Infections (SSIs) associated with these procedures SSI rates for: •Day 10 surveillance window •Day 30 readmission surveillance, if collected
Date of Response: 23/04/2026
View Response: 11331.pdf
Freedom of Information Request Reference: 11330
Date Received: 25/03/2026
Summary:
Please provide the following information: Whether NHS Lothian has had any contact, meetings, correspondence, or discussions with Palantir Technologies Inc., or any of its subsidiaries or associated companies, between 1 January 2020 and the date of this request. If so, please provide dates, attendees, and subject matter. Whether NHS Lothian has been approached by NHS England, the Department of Health and Social Care, or any UK Government body regarding adoption of the NHS England Federated Data Platform operated by Palantir Technologies. Whether any patient data held by NHS Lothian is currently accessible via, or has been shared with, the NHS England Federated Data Platform or any Palantir-operated system. Whether NHS Lothian has conducted or intends to conduct a Data Protection Impact Assessment in relation to any actual or proposed use of Palantir Technologies software or services.
Date of Response: 06/05/2026
View Response: 11330.pdf
Freedom of Information Request Reference: 11329
Date Received: 25/03/2026
Summary:
Please provide the following information for the period 1 January 2024 to 1 January 2025 most recent date available: 1. The number of patients for whom your organisation has arranged, funded, or reimbursed travel outside Scotland (including to England) for abortion services. 2. The number of patients referred to independent sector providers, such as, but not limited to, the British Pregnancy Advisory Service, for abortion care. Where possible to name the provider, please do. 3. The total annual amount paid by your organisation to independent sector providers for abortion services. If possible, please distinguish between: • Procedure/treatment costs • Administrative or contractual fees 4. The total annual cost incurred by your organisation in funding or reimbursing: • Patient travel (e.g. flights, rail, taxis) • Accommodation • Subsistence or related expenses 5. Please confirm whether your organisation centrally records: • The number of patients travelling outside Scotland for abortion care • The total cost associated with such cases
Date of Response: 24/04/2026
View Response: 11329.pdf
Freedom of Information Request Reference: 11328
Date Received: 24/03/2026
Summary:
1. Waiting times for diagnostic assessment for Alzheimer’s disease For the most recent 12 month period for which data is available, please provide: • The average, median, shortest, and longest waiting times from GP referral to initial memory clinic appointment. • The same waiting time metrics for the full pathway from: GP referral → memory clinic initial assessment → diagnostic assessment → confirmed diagnosis (where applicable). 2. Number of patients • The number of individuals referred by GPs to memory services for suspected Alzheimer’s disease in the same period. • The number who received a confirmed diagnosis. 3. Service capacity • Current staffing levels (WTE) for memory assessment services (e.g., psychology, psychiatry, specialist nurses, allied health professionals). • Any documented service pressures, backlogs, or recovery plans relating to memory assessment waiting times.
Date of Response: 29/04/2026
View Response: 11328.pdf
Freedom of Information Request Reference: 11327
Date Received: 24/03/2026
Summary:
Please can you provide the full NHS Lothian policy for shared care of ADHD medication?
Date of Response: 17/04/2026
View Response: 11327.pdf
Freedom of Information Request Reference: 11326
Date Received: 23/03/2026
Summary:
1. What Additional Pharmaceutical Care Services or Locally Enhanced Pharmaceutical Care Services are currently provided by community pharmacies in NHS Lothian. Please include any services which are not commissioned as part of the nationally negotiated pharmacy contract 2. The number of pharmacies which have agreed to provide each service 3. The total spending (including fixed retainers and activity-based payments) for each service for the last full financial year in which it is available. If the service is provided under a block contract, please provide the annual contract value for the most recent financial year available.
Date of Response: 22/04/2026
View Response: 11326.pdf
Freedom of Information Request Reference: 11324
Date Received: 23/03/2026
Summary:
1. The length in time in weeks that adults have had to wait for a tooth extraction in a) 2024/25 and b) 2025/26. 2. The length in time in weeks that children under 18 have had to wait for a tooth extraction in a)2024/25 and b) 2025/26.
Date of Response: 21/04/2026
View Response: 11324.pdf
Freedom of Information Request Reference: 11323
Date Received: 23/03/2026
Summary:
1. What the (a) longest and (b) average waiting time has been in each year since 2023 for all new outpatients under the age of 18 for dental specialties? 2. What the (a) longest and (b) average waiting time has been in each year since 2023 for all inpatient or day case admissions under the age of 18 for dental specialties?
Date of Response: 21/04/2026
View Response: 11323.pdf
Freedom of Information Request Reference: 11322
Date Received: 23/03/2026
Summary:
Please provide the following information: - The number of Specialist Grade, Specialist Grade Specialty and Associate Specialist (SAS) dentists currently employed by the Health Board. If possible, I would be grateful if you could also include: •A breakdown by service area or department •Whether these posts are full time or part time
Date of Response: 20/04/2026
View Response: 11322.pdf
Freedom of Information Request Reference: 11321
Date Received: 23/03/2026
Summary:
My request relates to "never events" or "wrong-site operations" - described as a medical error where a procedure is performed on the wrong patient, the wrong body part, or the wrong side of the body. Could you please provide the number of these incidents recorded and, where possible, the details involved in such incidents (ie what the identified error consisted of). Could this request cover the following time periods and be broken down as such. 2025 2024 2023 2022 2021
Date of Response: 22/04/2026
View Response: 11321.pdf
Freedom of Information Request Reference: 11319
Date Received: 23/03/2026
Summary:
I’d like to request a copy of the David J Bowles & Associates Ltd (2012) report titled “Investigation into Management Culture in NHS Lothian”.
Date of Response: 17/04/2026
View Response: 11319.pdf
Freedom of Information Request Reference: 11318
Date Received: 20/03/2026
Summary:
I would be grateful if you could confirm whether your trust holds the following information, and if so, provide copies or links where available: 1. Policies and Procedures Does your trust have any formal policies, pathways, or standard operating procedures that reference the care of neurodivergent patients during labour and birth? If so, please provide copies or links. 2. Guidelines or Protocols for Staff Does your trust provide any guidance or protocols for staff relating to communication approaches, sensory adjustments, reasonable adjustments, or other supportive care for neurodivergent patients during the intrapartum period? If so, please provide copies or links. 3. Resources, Tools, or Training Materials Does your trust use any resources, tools, or training materials (e.g. visual aids, communication tools, sensory supports, or staff training resources) to support neurodivergent patients during labour and birth? If so, please provide copies, links, or a brief description.
Date of Response: 17/04/2026
View Response: 11318.pdf
Freedom of Information Request Reference: 11317
Date Received: 20/03/2026
Summary:
The previous response stated that while NHS Lothian does not routinely refer staff to private providers, the need has arisen in a "very limited number of cases" for "Treatment & Assessment". To better understand this process, please provide the following information: Selection Criteria: Provide the specific clinical or administrative criteria used by the Occupational Health and Safety Service to determine when a staff member qualifies for a private sector referral for "Treatment & Assessment". Internal Policy/SOP: Please provide a copy of the formal policy, guideline, or Standard Operating Procedure (SOP) that governs the referral of NHS staff to private healthcare providers via Occupational Health. Exhaustion Protocol: Does NHS Lothian require that all "out of Lothian" NHS service options be exhausted before a private referral is considered? If so, please provide the documentation or protocol that outlines this requirement. Decision-Making Authority: Please specify which role or department within NHS Lothian holds the final budget-holding authority to approve the costs associated with these private referrals, such as those listed for 2023 and 2024. Mental Health Specifics: Regarding the "Treatment & Assessment" category, please clarify if this includes referrals for secondary psychiatric or psychological input when local NHS Lothian mental health services are deemed unavailable or unsuitable for the staff member.
Date of Response: 21/04/2026
View Response: 11317.pdf
Freedom of Information Request Reference: 11316
Date Received: 20/03/2026
Summary:
1. Where, if at all, does the Health Board carry out lumbar punctures (cerebrospinal fluid) for diagnosing patients with Alzheimer’s Disease? Lumbar punctures carried out within the Trust itself Lumbar punctures referred elsewhere and carried out external to the Trust Trust does not carry out lumbar punctures to diagnose Alzheimer’s Disease 2. Please provide a list of the full names of other Trusts or other organisations to which the Trust refers patients for lumbar puncture procedures in the diagnosis of Alzheimer’s Disease. 3. How many lumbar puncture procedures to test for Alzheimer’s Disease were performed in the last three-month period for which data are available? 4. Where, if at all, does the Health Board carry out Blood Biomarker (BBM) tests for diagnosing NHS patients with Alzheimer’s Disease? Pathology laboratory within the Trust Pathology laboratory external to the Trust Trust does not test for BBMs to diagnose Alzheimer’s Disease 5. Please provide a list of the full names of other Trusts or other organisations, to which the Trust refers Blood Biomarker tests for the diagnosis of Alzheimer’s Disease for NHS patients. Full name of Trust or organisation(s) 6. Please provide the number of BBM tests for Alzheimer’s Disease conducted over the last three-months, regardless of whether they were carried out within your organisation or sent to an external pathology laboratory. 7. Which of the following biomarker tests were used to detect Alzheimer’s Disease? pTau181 immunoassay tests pTau217 immunoassay tests 8. Please provide a list of the full names of other Trusts or other organisations, to which the Trust refers samples for pTau181 and pTau217 immunoassay testing for Alzheimer’s Disease? 9. How many pTau181 immunoassay tests were conducted to test for Alzheimer's Disease in the last three-months? 10. Is pTau181 testing for Alzheimer’s Disease linked to, or conducted in conjunction with, clinical trials? 11. How many pTau181 immunoassay tests were conducted for Alzheimer's Disease as part of a clinical trial? 12. How many pTau217 immunoassay tests were conducted to test for Alzheimer's Disease in the last three-months? 13. Is pTau217 testing for Alzheimer’s Disease linked to, or conducted in conjunction with, clinical trials? 14. How many pTau217 immunoassay tests were conducted for Alzheimer's Disease as part of a clinical trial? 15. Does your organisation participate in any of the following clinical trials? READ-OUT ADAPT Other(s) please specify below: 16. Which of the following metrics are used by the Trust to measure Blood Biomarker in the diagnosis of Alzheimer’s Disease? Number of tests Number of kits Number of runs Number of units Number of patients
Date of Response: 21/04/2026
View Response: 11316.pdf
Freedom of Information Request Reference: 11314
Date Received: 19/03/2026
Summary:
Please provide the following information for your Trust/hospital site(s) for the most recent complete 12-month period available (please state the exact start and end dates used). If your data are only available at Trust level (not site level), please provide Trust-level figures and state this explicitly. 1) Surgical specialties in scope Please report data separately for each of the following specialties (use the exact labels below): a) Cardiothoracic Surgery b) General Surgery (including: breast, colorectal, endocrine, upper GI, lower GI, and transplant—kidney, liver, pancreas) c) Neurosurgery d) Oral & Maxillofacial Surgery e) ENT / Otolaryngology f) Paediatric Surgery g) Plastic Surgery h) Trauma & Orthopaedic Surgery i) Urology j) Vascular Surgery If a specialty is not provided at your Trust/hospital site(s), please record 0 for that specialty and note “not provided”. 2) Workforce (headcount) For each specialty listed above, please provide: •Number of Consultant surgeons (substantive/headcount) •Number of SAS surgeons (headcount) (i.e., Specialty Doctor and Specialist grades) Please provide headcount (not WTE). If you can only provide WTE, please state that clearly. 3) Population served Please provide the total population served by your Trust/hospital (the figure you use for planning/catchment), and specify the source/definition used (e.g., “ICS population”, “catchment population”, etc.). 4) Surgical admissions activity Please provide the total number of admissions (elective + emergency combined) to all surgical specialties in scope (i.e., the combined total across the 10 specialties listed above) for the same 12-month period. If your admissions data are recorded using a different specialty grouping, please map as closely as possible and explain any assumptions.
Date of Response: 20/04/2026
View Response: 11314.pdf
Freedom of Information Request Reference: 11313
Date Received: 19/03/2026
Summary:
Q1. Does your trust treat Polycythaemia Vera (ICD10 code D45)? If no, please provide the name of the trust that you refer Polycythaemia Vera patients to? Q2. How many patients were initiated on Ruxolitinib (Jakavi) in the past 6 months for the following conditions? (Patients are classed as initiated if they have not received any of the above treatments in the previous 6 months) • Myelofibrosis (ICD10 code D47.4) • Polycythaemia Vera (ICD10 code D45) • Graft vs Host Disease (GvHD) (ICD10 code T86.0 or D89.8) (SNOMED Code: SCTID: 234646005) Q3. How many patients were initiated with the following regimens for any condition in the past 6 months? (Patients are classed as initiated if they have not received any of the above treatments in the previous 6 months) • Momelotinib • Fedratinib Q4. How many patients were treated in the past 6 months for Polycythaemia Vera (ICD10 code D45) with? • Hydroxycarbamide • Interferon therapy Q5. Of the myelofibrosis (ICD10 D47.4) patients receiving the following treatments in the past 6 months, please indicate how many were receiving their first systemic therapy (First systemic therapy = patient has not previously received any drug treatment for myelofibrosis, including hydroxycarbamide, interferon therapy, JAK inhibitors, or other systemic therapy. Excludes a watch and wait approach.) Treatment First systemic therapy Received prior systemic therapy Ruxolitinib (Jakavi) Fedratinib (Inrebic) Momelotinib (Omjjara) ICO reference
Date of Response: 20/04/2026
View Response: 11313.pdf
Freedom of Information Request Reference: 11312
Date Received: 18/03/2026
Summary:
Please could I request the following information: • Total spend on Clinical Insourcing from January 2026 until present • Breakdown of the companies used and for what specialties they were used in • Total spend on Outsourcing from January 2026 until present • Breakdown of the companies used and for what specialities they were used in
Date of Response: 17/04/2026
View Response: 11312.pdf
Freedom of Information Request Reference: 11311
Date Received: 18/03/2026
Summary:
For each year that the data has been collected, up until the most recently available complete year of data, I would like to know: 1) How many patients under the care of the gender clinic died 2) How many of these patients died by suicide or suspected suicide 3) The number of patients in 2) broken down into those patients who were a) on the waiting list for a first appointment with the gender clinic b) had had their first appointment at the gender clinic and c) had been referred by the gender clinic on to endocrinology or for surgery.
Date of Response: 17/04/2026
View Response: 11311.pdf
Freedom of Information Request Reference: 11310
Date Received: 18/03/2026
Summary:
1. How many patients are currently on the West Lothian Adult Neurodevelopmental disorders waiting list? 2. How many clinicians are currently available to provide appointments for patients waiting on the West Lothian Adult Neurodevelopmental disorders Service waiting list as of March 2026? 3. What is the Speciality breakdown of clinical staff currently providing appointments for patients waiting on the West Lothian Adult Neurodevelopmental disorders Service waiting list as of March 2026. Broken down by numbers of staff from each clinical speciality category? 4. What is the average wait for a patient from the point of being added to the West Lothian Adult Neurodevelopmental disorders waiting list to first appointment with a clinician? 5. Since patients were informed of a review of the West Lothian NDD list in September 2025 what percentage of those on the waiting list have been contacted to confirm they wish to remain on the list as of March 2026? 6. Can you confirm that NHS Lothian / West Lothian Health and Social Care Partnership are continuing to give appointments to adults referred to the NDD waiting list who have been referred for ADHD-only assessments and there has been no pause in the provision of appointments in order to only prioritise those with co-occurring mental health conditions. 7. How many patients on the West Lothian Adult Neurodevelopmental disorders waiting list have received an ADHD only assessment, in the last 12 months, to March 2026.
Date of Response: 28/04/2026
View Response: 11310.pdf
Freedom of Information Request Reference: 11308
Date Received: 17/03/2026
Summary:
Please provide the following information on NHS chaperone policies, training and reporting: 1) Current chaperone policy or policies relating the use of formal and informal chaperones. 2) Associated procedures & guidelines including: a) Guidance on how the offer, acceptance, or refusal of a chaperone must be recorded in patient notes. b) Guidance on how the sex of the chaperone is recorded. 3) If your policy/procedures/guidelines have been withdrawn, please provide: a) the most recent version. b) the date it was placed under review or withdrawn. c) the communications with staff when it was put under review or withdrawn. d) the timetable for development and approval of any replacement policy e) details of internal and external consultation lists. 4) If not included in the policy/procedures/guidelines, please also disclose: a) training and competency standards for staff acting as formal chaperones. b) training description and provision for chaperones (eg online, in person, what organisations delivers the training and outline). 5) Audit reports, quality assurance reviews, compliance monitoring, and management and/or board reports relating to chaperoning 2024 to date. 6) Related equality impact assessments (EIAs) if separate 7) Datix reports: a) Number of Datix reports raised related to chaperoning in 2024, 2025 and 2026 Jan & Feb, by sex of patient and chaperone & definition of sex field in Datix. b) If you record this data by gender, please disclose the Number of Datix reports raised related to chaperoning in 2024, 2025 and 2026 Jan & Feb, by gender of patient and chaperone and definition of gender field in Datix. 8) Concerns: a) Number of concerns raised by chaperones, if not recorded via Datix, in 2024, 2025 and 2026 Jan & Feb, by sex of patient and chaperone & definition of sex field. b) If you record this data by gender, please disclose the number of concerns raised by chaperones in 2024, 2025 and 2026 Jan & Feb, by gender of patient and chaperone and definition of gender field. 9) Complaints: a) Number of complaints raised related to chaperoning in 2024, 2025 and 2026 Jan & Feb, by sex of patient and chaperone & definition of sex field in your complaints system. b) If you record this data by gender, please disclose the number of complaints raised related to chaperoning in 2024, 2025 and 2026 Jan & Feb, by gender of patient and chaperone and definition of gender field in your complaints system. c) Number of Freedom to Speak Up reports related to chaperones in 2024, 2025 and 2026 Jan & Feb by sex of the reporter. d) If you record this data by gender, please disclose the number of cFTSU reports related to chaperoning in 2024, 2025 and 2026 Jan & Feb, by gender of the reporter.
Date of Response: 01/05/2026
View Response: 11308.pdf
Freedom of Information Request Reference: 11307
Date Received: 17/03/2026
Summary:
I request disclosure of the following information relating to Quail AI tool for complaints in Healthcare. I would be grateful if you could answer the following: Implementation and Usage • Has your organisation implemented or piloted the Quail AI tool for complaints handling? • If yes: o Date of implementation o Scope of use (e.g. departments, complaint types, Trust-wide or pilot) 2. Accuracy and Quality Assurance • What measures are in place to assess the accuracy of Quail-generated responses? • Has your organisation conducted any formal evaluation or audit of the accuracy or quality of letters generated using Quail? • If so, please provide: o Results of such evaluations o Any internal reports, audits, or summaries 3. Human Oversight and Editing • What percentage of Quail-generated complaint responses require: o Minor edits o Significant edits o Complete rewriting • Are clinicians or complaints staff required to review all AI-generated responses before they are sent? 4. Impact on Complaints Handling • Has the use of Quail: o Reduced complaint response times? If so, by how much (average time reduction)? o Improved response rates or compliance with statutory timelines? o Reduced workload for complaints teams or clinicians? 5. Service User Feedback • Has your organisation received any feedback from patients or service users regarding AI-generated complaint responses? • If so, please provide: o Themes of feedback o Number of complaints or concerns raised about AI-generated responses 6. Clinical and Investigative Quality • Has the use of Quail impacted: o The quality of investigations? o The quality of clinical input within complaint responses? • Please provide any available evidence, reports, or internal assessments. 7. Governance, Risk, and Safety • What governance processes are in place to oversee the use of AI in complaints handling? • Have any risks, incidents, or concerns been identified relating to: o Accuracy o Patient safety o Miscommunication • If so, please provide details (anonymised where appropriate). 8. Data Protection and Information Governance • What data protection impact assessments (DPIAs) or information governance reviews have been completed in relation to Quail? • Please provide copies or summaries of these assessments. 9. Costs and Procurement • What is the cost of implementing and using Quail (including licensing, training, and ongoing costs)? • Please provide details of the procurement process and supplier. 10. Future Plans • Does your organisation plan to: o Continue using Quail? o Expand its use (e.g. incident reporting modules)? • Please provide any available business cases or strategy documents.
Date of Response: 16/04/2026
View Response: 11307.pdf
Freedom of Information Request Reference: 11306
Date Received: 17/03/2026
Summary:
I would be grateful if you could provide the following documents or information: 1. Any Standard Operating Procedures (SOPs), operational policies, or local protocols that specifically refer to the identification, assessment, or support of carers by the Rapid Response Team. 2. Any formal referral pathways or checklists used by the RRT to signpost carers to third-sector organizations or local authority support services. 3. Any service specification or operational guidance that outlines the expected input or interventions carers should receive from the RRT during a crisis episode.
Date of Response: 16/04/2026
View Response: 11306.pdf
Freedom of Information Request Reference: 11305
Date Received: 17/03/2026
Summary:
Q1. Does your Trust treat patients for Lupus Nephritis? (ICD-10 Code: M32.14 SNOMED Code: 68815009) If the Trust doesn’t treat patients for Lupus Nephritis, to which Trust does the Trust refer patients on for treatment? Q2. How many patients have a current diagnosis of Lupus Nephritis? Please can you look at the last three full calendar years of data (2023, 2024, 2025) and provide a total number of patients who had a diagnosis in each year (ICD-10 Code: M32.14 SNOMED Code: 68815009). Q3. How many patients have received treatment in the latest four-month period (November 2025 to February 2026 if available) for Lupus Nephritis with the following treatments regimens? (ICD-10 Code: M32.14 SNOMED Code: 68815009) •Standard Therapy (Steroids + Mycophenolate Mofetil (MMF)) •Cyclophosphamide (EuroLupus regimen) •Belimumab (Benlysta) •Voclosporin (Lupkynis) •Obinutuzumab (Gazyvaro) •Ritixumab (MabThera or biosimilars) •Rituximab (any other brand) •Any other targeted therapy (please state if possible)
Date of Response: 28/04/2026
View Response: 11305.pdf
Freedom of Information Request Reference: 11300
Date Received: 16/03/2026
Summary:
I am writing to request data on your trust’s pharmacy workforce for each of the financial years from 2020/2021 to 2024/2025 under the Freedom of Information Act. Please provide the data in the below tables, if possible: 1. Total number of pharmacy staff for each year, including headcount and full-time equivalent (FTE) 2. Pharmacy workforce by agenda for change band, including headcount (HC) and full-time equivalent (FTE)
Date of Response: 28/04/2026
View Response: 11300.pdf
Freedom of Information Request Reference: 11299
Date Received: 13/03/2026
Summary:
We are looking for information on your registered nurse (band 5 and above) bank shifts. If possible, please exclude midwifery staff from any data you send. 1. Please tell us - how many bank shifts were worked at your trust by registered nurses during the periods below. Please set out these shifts by Agenda for Change (AfC) pay band, if possible 2. Please tell us – the total amount spent by your trust on bank shifts worked by registered nurses during the periods below. Please set out the amounts spent by Agenda for Change (AfC) pay band, if possible. If it is not possible to provide this by band, please give the total amount 3. Does your organisation offer a variety of registered nurse bank shifts at different pay bands (such as in tables above) or does it instead adopt a ‘flat rate’ per hour that all bank nurses would receive? (i) If it adopts a ‘flat rate’ please detail what the hourly rate is for all registered nurses. E.g: £15.88 hourly rate 4. Have there been any changes to your bank shift policy for registered nursing staff since January 2024? If so, please explain what these changes were.
Date of Response: 20/04/2026
View Response: 11299.pdf
Freedom of Information Request Reference: 11298
Date Received: 13/03/2026
Summary:
1. Please provide the overall spend so far on agency non-clinical staff in each financial year since 2022-23. Please break this down by job type e.g. admin, facilities etc 2. Please provide the overall spend so far on bank non-clinical staff in each financial year since 2022-23. Please break this down by job type e.g. admin, facilities etc
Date of Response: 20/04/2026
View Response: 11298.pdf
Freedom of Information Request Reference: 11297
Date Received: 13/03/2026
Summary:
1. How many attendances have there been at the GP walk-in centre which has opened in your health board? Please break this down by week. 2. So far, what is the estimated cost of setting up the walk-in centre in your health board? Please provide as much detail as possible. 3. How many staff members are working in these centres? Please break this down by occupation type, e.g. GP, receptionist etc
Date of Response: 20/04/2026
View Response: 11297.pdf
Freedom of Information Request Reference: 11296
Date Received: 13/03/2026
Summary:
Q1. How many patients were treated in the last 3 months with any systemic anti-cancer therapies for Gastric cancer or cancer of the Gastro-Oesophageal Junction? Q2. How many patients were treated in the past 3 months for gastric cancer (any stage) with: • CAPOX (Capecitabine with Oxaliplatin) • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) • Lonsurf (Trifluridine - tipiracil) • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Pembrolizumab (any formulation) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Pembrolizumab (395 mg or 790mg solution for injection only) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Zolbetuximab (Vyloy) • Any other systemic anti-cancer therapy • Palliative care only Q3. How many patients were treated in the past 3 months for cancer of the gastro-oesophageal junction (any stage) with: • CAPOX (Capecitabine with Oxaliplatin) • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) • Lonsurf (Trifluridine - tipiracil) • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Pembrolizumab (any formulation) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Pembrolizumab (395 mg or 790mg solution for injection only) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Zolbetuximab (Vyloy) • Any other systemic anti-cancer therapy • Palliative care only Q4. If you have been unable to answer any of the above questions because you do not treat Gastric or Gastro-Oesophageal Cancer, to which site do you refer patients that require either treatment?
Date of Response: 13/04/2026
View Response: 11296.pdf
Freedom of Information Request Reference: 11292
Date Received: 11/03/2026
Summary:
Of that yearly cohort, how many experienced a spinal cord injury as a result of their surgery (or as a result of post op complications) - includes but not limited to ischaemia of the spinal cord.
Date of Response: 20/04/2026
View Response: 11292.pdf
Freedom of Information Request Reference: 11290
Date Received: 11/03/2026
Summary:
Can I request the following, broken down by the calendar years 2019, 2023, 2024 and 2025 (most recent): 1. The median wait (in days) between the initial meeting (assessment/choice appointment), where a CAMHS professional will talk to the child or young person who is unwell, listen to their symptoms and decide on how to help them, and the start of treatment. 2. The longest wait (in days) between the initial meeting (assessment/choice appointment), where a CAMHS professional will talk to the child or young person who is unwell, listen to their symptoms and decide on how to help them, and the start of treatment.
Date of Response: 21/04/2026
View Response: 11290.pdf
Freedom of Information Request Reference: 11289
Date Received: 11/03/2026
Summary:
I would like to request a review of this FOI response as I have FOI'd every Health Board in Scotland this request - and other than a delayed apology from Grampian - I have been able to get the data from every other one. I would be quite surprised that Lothian does not follow the same data gathering rules when regarding Child Dentistry as the other health boards.
Date of Response: 16/04/2026
View Response: 11289.pdf
Carer Positive Icon
Awards Aware Icon
We are a Living wage Employer Icon
Duke of Edinburgh's Award Logo
Young Person's Guaranteed Employer Logo
Scottish Top Employers Logo
Disability Confident Employer Logo
 
CONTACT NHS LOTHIAN
Lothian NHS Board
Mainpoint
102 Westport
Edinburgh
EH3 9DN

Main Switchboard: 0131 242 1000
YOUR RIGHTS
OUR VALUES INTO ACTION
Around 3,000 colleagues across NHS Lothian have developed Our Values, a set of common values and ways of working - to the benefit of everyone working in the organisation and, most importantly - to the benefit of our patients.
WORKING WITH NHS LOTHIAN
MEDIA ENQUIRIES
STAY CONNECTED TO NHS LOTHIAN
Facebook
Twitter
YouTube
Vimeo
Instagram
PARTNERS
NHS Lothian Charity Logo
Tel: +44 (0)131 465 5850
Email: loth.charity@nhs.scot

Scottish Registered Charity No: SC007342
The official charity of NHS Lothian.
From the everyday to the transformational, we support NHS Lothian to excel for all the communities it serves: patients, families, carers and staff.
Making healthcare better, together.
Find out more about NHS Lothian Charity
Donate